| Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts KA Hutcheson, BZ Atkins, MT Hueman, MB Hopkins, DD Glower, ... Cell Transplantation 9 (3), 359-368, 2000 | 286 | 2000 |
| Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients GE Peoples, JM Gurney, MT Hueman, MM Woll, GB Ryan, CE Storrer, ... Journal of Clinical Oncology 23 (30), 7536-7545, 2005 | 278 | 2005 |
| Evolving treatment strategies for gallbladder cancer MT Hueman, CM Vollmer, TM Pawlik Annals of surgical oncology 16, 2101-2115, 2009 | 234 | 2009 |
| Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials … GE Peoples, JP Holmes, MT Hueman, EA Mittendorf, A Amin, S Khoo, ... Clinical Cancer Research 14 (3), 797-803, 2008 | 216 | 2008 |
| Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium BZ Atkins, MT Hueman, JM Meuchel, MJ Cottman, KA Hutcheson, ... The Journal of heart and lung transplantation 18 (12), 1173-1180, 1999 | 185 | 1999 |
| Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine JP Holmes, LC Benavides, JD Gates, MG Carmichael, MT Hueman, ... Journal of Clinical Oncology 26 (20), 3426-3433, 2008 | 155 | 2008 |
| Cellular cardiomyoplasty improves diastolic properties of injured heart BZ Atkins, MT Hueman, J Meuchel, KA Hutcheson, DD Glower, DA Taylor Journal of Surgical Research 85 (2), 234-242, 1999 | 145 | 1999 |
| The impact of HER2/neu expression level on response to the E75 vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 LC Benavides, JD Gates, MG Carmichael, R Patel, JP Holmes, ... Clinical Cancer Research 15 (8), 2895-2904, 2009 | 135 | 2009 |
| Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology ZA Dehqanzada, CE Storrer, MT Hueman, RJ Foley, KA Harris, YH Jama, ... Oncology reports 17 (3), 687-694, 2007 | 112 | 2007 |
| Surgical diseases presenting in pregnancy CS Dietrich III, CC Hill, M Hueman Surgical Clinics of North America 88 (2), 403-419, 2008 | 104 | 2008 |
| Management of retroperitoneal sarcomas MT Hueman, JM Herman, N Ahuja Surgical clinics of north America 88 (3), 583-597, 2008 | 85 | 2008 |
| Tumour location within the breast: Does tumour site have prognostic ability? S Rummel, MT Hueman, N Costantino, CD Shriver, RE Ellsworth Ecancermedicalscience 9, 2015 | 82 | 2015 |
| Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence From US Military Cancer Institute Clinical Trials Group … JP Holmes, JD Gates, LC Benavides, MT Hueman, MG Carmichael, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 69 | 2008 |
| Levels of circulating regulatory CD4+ CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★ MT Hueman, A Stojadinovic, CE Storrer, RJ Foley, JM Gurney, CD Shriver, ... Breast cancer research and treatment 98, 17-29, 2006 | 66 | 2006 |
| Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients MT Hueman, ZA Dehqanzada, TE Novak, JM Gurney, MM Woll, GB Ryan, ... Clinical cancer research 11 (20), 7470-7479, 2005 | 63 | 2005 |
| Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial R Patil, GT Clifton, JP Holmes, A Amin, MG Carmichael, JD Gates, ... Journal of the American College of Surgeons 210 (2), 140-147, 2010 | 60 | 2010 |
| Management of gastrointestinal stromal tumors MT Hueman, RD Schulick Surgical Clinics of North America 88 (3), 599-614, 2008 | 57 | 2008 |
| Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients ZA Dehqanzada, CE Storrer, MT Hueman, RJ Foley, KA Harris, YH Jama, ... Clinical cancer research 12 (2), 478-486, 2006 | 55 | 2006 |
| Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine MT Hueman, A Stojadinovic, CE Storrer, ZA Dehqanzada, JM Gurney, ... Cancer Immunology, Immunotherapy 56, 135-146, 2007 | 48 | 2007 |
| Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds FA Lisboa, MJ Bradley, MT Hueman, SA Schobel, BJ Gaucher, ... Surgery 161 (4), 1164-1173, 2017 | 40 | 2017 |
